Table 3

Adjuvant therapy: monitoring of group 1 patients

CK+ cells/2 × 106 MNC BMaHer-2/neuCK+ cells/ml PBSCCK+ cells/2 × 106 MNC BMbTTPc (mo)OS (mo)
10n.d.036 +42 +
200n.d.1242 +
326#105#031 +39 +
400023 +35 +
500026 +33 +
600017 +34 +
70Positive0025 +32 +
82#0019 +29 +
940022 +28 +
100n.d.n.d.17 +25 +
110n.d.0615
120110#n.d.26 +32 +
130n.d.n.d.LFULFU
  • a Before therapy.

  • b After therapy.

  • c TTP, time to progression; #, and 17-1A positive; LFU, lost to follow-up; n.d., not determined.